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From the Director
This has been a busy year for the Law & Health Care Program.
We celebrated the 20th Anniversary of the Journal of Health Care
Law & Policy, hosted the 7th Annual Health Law Regulatory
and Compliance Competition, welcomed 2018 Rome Lecturer,
Dr. Aaron Kesselheim of the Harvard School of Medicine, and
collaborated with the Johns Hopkins Berman Institute of Bioethics
on a joint faculty retreat. In this issue, we also highlight the work on
the opioid epidemic of L&HCP faculty, as well as faculty and staff
from our affiliate programs, the Center for Health and Homeland
Security and the Legal Resource Center for Public Health Policy.
We hope you enjoy our Summer Issue.
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he opioid epidemic in the United States remains a serious public
health concern with severe negative consequences for the individuals
struggling with addiction, their families, and surrounding communities.
In 2016, the most recent year for which data are available, more than 11
million people misused prescription opioid medication and more than
42,000 individuals died as a result of an opioid overdose (i.e. overdose
from prescription opioids, heroin, and fentanyl).1,2 In recognition of the
devastating impact of opioid abuse, in October 2017, the Acting Secretary
of Health and Human Services declared the opioid crisis a public health
emergency.3

Microbiota Transplant Project
Update

T

Faculty and staff within the Law & Health Care Program at the University
of Maryland Francis King Carey School of Law have been actively
engaged in research, clinical work, and advocacy related to the epidemic.
Professor Amanda Pustilnik recently completed an analysis of the origins
of the epidemic and conditions, particularly the legal and policy factors,
which contributed to its spread. Her research on the epidemic was included
as a chapter in the Aspen Institute’s report “Confronting Our Nation’s
Opioid Crisis,” published in late 2017.4 (Continued on next page)
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In “The Law’s Responses to the
Opioid Epidemic,” Pustilinik provides
a comprehensive overview of the
events (namely approval of OxyContin
in 1996), agencies (FDA, DEA, CMS,
among others) and laws (such as
the Controlled Substances Act) that
have played a part in the increased
use of opioids and subsequent spike
in rates of addiction and overdose.
As Pustilnik notes, the “large set of
actors, with quite disparate mandates,
powers and policies can create
inconsistencies and coordination
problems in responding to the national
drug epidemic.”4 At the same time,
however, this complex framework
provides opportunity for innovative
legal approaches.
At the federal level, there was a push
during the Obama Administration
to integrate efforts in the health
and criminal law contexts with an
emphasis on treatment and improved
care, an acknowledgement that
previous efforts focused on punitive
measures and incarceration had been
ineffective in addressing the crisis.
Under the current administration, the
future direction of federal policy is
unclear. As a result, much of the push
for innovative approaches to the opioid
epidemic is occurring at the state
level. There is, for example, increasing
reliance on data to allow states to
identify troubling prescription patterns
and high-risk areas and individuals.
Prescription drug monitoring programs
(PDMPs) are one example of this type
of data-driven initiative. States are
able to identify providers engaged in
questionable prescribing practices as
well as patients who may be doctor
shopping.
Other efforts at the state level include
increased funding and expanded
access to medication-assisted
treatment, such as methadone, which
has demonstrated higher effectiveness
than more conventional addiction
recovery programs. Harm reduction is
another increasingly popular approach

among legislators. Safe injection
facilities that allow individuals to
use drugs under medical supervision
have been opened in West Virginia
and Washington State with similar
legislation pending in several
other states. Other legislative harm
reduction strategies include so-called
Good Samaritan and safe harbor
laws that are designed to encourage
individuals to seek assistance in the
case of drug overdose without fear
of criminal prosecution or other legal
repercussions.

Prof. Amanda Pustilnik

There remain, however, significant
legal obstacles to local, state and
federal efforts to curb opioid abuse.
These include conflicts between these
new legislative efforts and existing
federal laws grounded in an outdated
perspective on drug addiction as
a moral failure and a voluntary
behavior that governments should
not incentivize through provision of
treatment services.
Evidence of substance abuse can
prevent access to social services
programs such as Medicaid, the
Supplemental Nutritional Assistance
Program and Temporary Assistance for
Needy Families. According to Prof.
Pustilnik’s analysis, as of March 2017,
fifteen states mandated drug testing for
recipients of state-administered federal
benefit programs. Such rules have
an inherent conflict with evidencebased approaches to the epidemic that
emphasize access to treatment.

As Pustilnik notes, opioid
manufactures have been able to reap
tremendous profits through product
sales but do not bear any of the costs
associated with improper use and
abuse of that product. That cost is
borne largely by state and federal
government and ultimately taxpayers.
Pustilnik argues that lawmakers
should adopt approaches that have
been successful for other public
health issues such as tobacco, drunk
driving, and environmental pollution.
These models, she argues, have been
successful in their ability to align
commercial interest with the public
interest by establishing penalties
and other sanctions that will provide
incentives for responsible corporate
behavior. She likens pharmaceutical
companies to bar operators – once
civil and criminal penalties were
imposed and enforced on operators
for selling excess amounts of alcohol
to patrons. Approaches that rely on
individual court cases, however, are
unlikely to have a large-scale deterrent
effect.
The Tobacco Master Settlement
Agreement serves as another potential
model. There are clear parallels
between the tobacco and opioid
industries – misrepresentations
of product risks and aggressive
marketing, among others. The
Settlement provides significant
compensation to states and places
strict restrictions on tobacco
marketing. Such a model could be
employed in the opioid context as
well. The model’s strengths lie in its
ability to begin to shift the costs of
the epidemic back to manufacturers
and may serve as a more effective
national strategy versus a case-by-case
litigation approach.
The epidemic of opioid abuse must
be addressed at all levels, i.e., local,
state and federal, with a multifaceted
approach that includes public health
and medical professionals as well as
policy, judicial, and law enforcement

entities. In order to adequately address
the root causes of the epidemic,
however, Pustilnik makes a convincing
argument that legal approaches
must focus on the actions of drug
manufacturers.
University of Maryland Center for
Health & Homeland Security Aids in
Maryland’s Response
In Maryland, opioid-related deaths
nearly quadrupled between 2010 and
2016 (final numbers for 2017 are still
pending but suggest that rates continue
to rise). In response, in March 2017,
Maryland Governor Larry Hogan
declared the opioid addiction crisis
a state of emergency. Since the
declaration, the staff at the University
of Maryland Center for Health and
Homeland Security (CHHS) has
been actively engaged in a statewide,
multiagency effort to combat and
prevent opioid addiction, overdose and
death.
CHHS staff member Birch Barron is
currently serving as Deputy Director
and Chief of Staff to Clay Lance,
the Senior Emergency Management
Advisor to the Governor, at the
Opioid Operational Command Center
(OOCC), the body responsible
for coordinating the state’s opioid
response. Prior to the establishment
of the OOCC, many agencies at the
state and local level were working
to address the opioid epidemic but
there was little communication or
coordination between agencies or
dissemination of best practices and
lessons learned.
The OOCC provides statewide
coordination of the many stakeholders
involved in addressing the crisis,
including the Maryland Emergency
Management Agency (MEMA), the
Maryland Department of Health
(MDH) as well as ten other state
agencies and representatives from all
twenty-four counties in the state.

Other members of the CHHS team
are also contributing to the effort.
Trudy Henson ‘08, CHHS Public
Health Program Director, and Michael
Tennison ‘15, Senior Law & Policy
Analyst, have been collaborating
with MEMA and the OOCC to write
the OOCC review and transition
report. The report examines activities
undertaken since the declaration,
identifies the legal issues that may
arise during a transition out of the
state of emergency and provides a
framework for that transition. The
report was completed in late February
but has not yet been released to the
public.

Trudy Henson

Maryland’s approach to the opioid
crisis, as a state of emergency rather
than a public health emergency, raises
many legal and policy issues. Trudy
Henson examines these with students
in her course Law and Policy of
Emergency Public Health Response.
Prof. Henson notes, “One reason
that Maryland chose to address the
opioid crisis under a general state of
emergency is that such a declaration
gives the Maryland Emergency
Management Agency jurisdiction and
one of MEMA’s strengths is its ability
to coordinate resources as well as
its incident command structure that
provides a ready-made framework for
the response. This approach recognizes
that the opioid crisis is not only a
public health issue but a problem that
has wide repercussions for education,
housing, and law enforcement among
(Continued on page 5)
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What about treatment for chronic pain?
In all of the debate surrounding the opioid epidemic, an important segment of the
population is often forgotten – patients suffering from chronic pain for which opioid
medication remains the only effective treatment. Diane Hoffmann, Professor and Director
of the Law & Health Care Program, has a longstanding research interest in the treatment of
chronic pain. In 1997, Hoffmann was named a Mayday Scholar by the Mayday Foundation,
an organization dedicated to alleviating the incidence and consequence of chronic pain. As
a result of that award, she has been able to examine the issue in depth and make important
contributions to the literature regarding the legal obstacles to the treatment of pain.
Hoffmann continues to examine the impact of the latest policy developments resulting
from the opioid epidemic. In fall 2017, she spoke to clinicians and researchers during Pain
Grand Rounds in the Department of Neurology and Neurosurgery at the Johns Hopkins
School of Medicine. In her talk “Legal and Ethical Challenges to the Treatment of Chronic
Pain Patients,” Prof. Hoffmann reviewed the collateral damage of prior attempts to address
the issue of opioid overprescribing, namely disciplinary and prosecutorial actions against
physicians treating chronic pain patients within the standard of care. This was due in part
to a lack of understanding of chronic pain treatment on the part of federal agencies and
state licensing boards responsible for oversight of physicians. Indeed, these entities have
struggled to establish and enforce a consistent standard for opioid prescriptions.
At the same time, there has been considerable pressure for state and federal agencies to
respond to the rapid increase in rates of opioid misuse and abuse. After many years without
a consistent policy, in 2016, the CDC issued guidelines for prescribing opioids to treat
chronic pain. The guidelines emphasize the importance of prescribing only when necessary,
at the lowest dose and for the shortest duration possible and only in the context of close
patient monitoring. The guidelines have spurred legislative action in many states and include
efforts to limit dosage and quantity of opioid prescribing. Many state Medicaid Programs
have also adopted the CDC guidelines and DEA has stepped up its enforcement, with a
significant increase in the number of administrative actions against physicians to remove
their registration to prescribe controlled substances as well as criminal prosecutions.
“I think it’s clear now in hindsight that the policy pendulum swung too far in the direction
of liberalization of opioid prescribing. Now I fear the pendulum is swinging too far in the
direction of restrictiveness,” said Hoffmann. “In the effort to combat the opioid epidemic,
state and federal authorities are depriving patients of an appropriate and effective treatment
for chronic pain.” Recently, Hoffmann co-wrote a letter to the editor of the Washington Post,
making these points in response to an op-ed criticizing an effort by Human Rights Watch
to look at the effects of opioid limits on the treatment of chronic pain (see Hoffmann and
Nicholson, Reasonable Questions on Opioids, Washington Post, May 16, 2018).
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many others.”
Local Level Approaches: The Legal
Resource Center for Public Health
Policy
The Legal Resource Center for Public
Health Policy (LRC), led by Professor
Kathleen Hoke, has been working
in the area of addictions since its
founding in 2001. Originally created
with funds from Maryland’s settlement
with tobacco companies, the Center
provides legal guidance to state and
local governments, lawmakers, nongovernmental organizations and health
advocacy groups. In the nearly twenty
years that the Center has been working
with local health officers, its attorneys
and staff have developed a
strong reputation as a reliable
resource for legal and
technical assistance. As local
agencies started to confront
the opioid epidemic, they
began contacting the LRC
for assistance.
Much of LRC’s work in the
context of opioids focuses on
the tracking of legislation in
Maryland and nationally. The
LRC, along with students
from the law school’s Public
Health Law Clinic, provides
concise summaries of all opioid
legislation introduced during the
Maryland legislative session as well
as weekly updates of each bill’s status,
hearing dates, etc. The LRC also holds
biweekly conference calls during
the legislative session that provide
stakeholders the opportunity to ask
questions about specific bills and share
information.
In the 2017 legislative session,
more than sixty opioid bills were
introduced in the Maryland General
Assembly. With such a high volume
of legislation, this tracking provides
critical support to local agencies
and organizations working to

improve public health. It also helps
to inform LRC’s work with the
Opioid Workgroup of the Health and
Government Operations Committee of
the Maryland General Assembly.
In addition to the legislative tracking,
LRC staff and student attorneys are
frequently called upon by lawmakers
to provide background research on
opioid-related initiatives in other
states. A state delegate, for example,
recently contacted the LRC to find
out what other states are doing to
encourage pregnant women to seek
treatment for opioid addiction. This is
a difficult population to reach given
the stigma associated with addiction
and fears that child protective services

will become involved.
Outside of the legislative session,
the LRC team spends time working
with local health departments,
giving presentations on the latest
developments in public health policy
at the state and national level. They
also work closely with the judiciary,
conducting educational sessions and
developing materials to inform judges
of policy changes (e.g. changes in
insurance coverage requirements)
that might influence decisions in the
sentencing phase of trials.

with the Baltimore Area Health
Education Center to offer semiannual
Interprofessional Education Training
to students from the University of
Maryland Baltimore professional
schools (Law, Medicine, Pharmacy,
Dentistry, Social Work, and Nursing).
Students analyze case studies, discuss
recent policy changes (e.g. Maryland’s
Good Samaritan Law which provides
legal protection to individuals to
encourage emergency service contact
in case of overdose) and receive
training in the administration of
Naloxone to prevent opioid overdose
deaths.
Professor Hoke is also engaged in
activities at the campus level through
the University’s Center for
Addiction Research, Education
and Services (CARES), an
interprofessional effort to
address the adverse impact of
addiction. Hoke serves on the
Steering Committee where
she contributes her expertise
in policy advocacy to inform
the Center’s efforts to provide
addiction-related policy
consultation and analysis to
local and state government
policy makers.
Through scholarship, advocacy
and technical assistance, Law &
Health Care Program faculty, staff
and students are making important
contributions to local, state and
national level efforts to address the
epidemic of opioid abuse and remain
committed to finding solutions. Multilevel, multidisciplinary approaches
that include a health law perspective
will be essential to these efforts.
(Continued on page 12)

LRC Staff Attorneys Mellissa
Sager and Brooke Torton work
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Journal of Health Care Law & Policy
Celebrates 20th Anniversary

T

he Journal of Health Care Law & Policy
recently celebrated its 20th Anniversary
with a dinner attended by faculty, current student
editors and alumni. The night was highlighted by
recollections from faculty on the Journal’s history
and accomplishments and from alumni on their
experiences working on the student-led publication.
After welcoming attendees, current Editor-InChief Hassan Sheikh and Managing Editor Eleanor
Chung introduced Professor Karen Rothenberg who
reflected on the Journal’s founding. She talked about
the initial vision behind the creation of the Journal,
a publication designed to disseminate the latest
research of leading scholars working in the area
Faculty, alumni, and student-editors gather at the Journal's
anniversary dinner.
of health law and policy. It also served the important
purpose of providing students with exposure to the latest
scholarship on leading issues in health law such as the Supreme Court's decision in the Cruzan case and implications
of the AIDS epidemic for health care workers. Initially used solely to publish articles generated from symposia hosted
by the Law & Health Care Program, after a few years the Journal was able to dedicate one issue per year to unsolicited
articles, cementing its status among legal academics in the field as well as interdisciplinary scholars and policy makers.
Law & Health Care Program Director and Professor Diane Hoffmann then offered remarks on the Journal’s many
accomplishments over the past two decades including its role as a resource for policy makers on cutting-edge issues.
The first issue published by the Journal, for example, focused on conducting medical research with individuals lacking
decision-making capacity and included articles by leading bioethicists and clinicians. Articles from the issue were later
cited by the National Bioethics Advisory Commission in its report on Research Involving Persons with Mental Disorders
that May Affect Decision-making Capacity.
Hoffmann noted that the Journal has also successfully established itself as a forum for
the publication of multidisciplinary perspectives on pressing topics in health law and
policy, attracting not only health lawyers but also medical researchers, physicians,
legislators, practicing lawyers, policy makers, bioethicists, industry representatives, and
patient advocates.

Deepti Kulkarni ’08

This multidisciplinary approach became the model for the Journal’s symposium issues.
The Journal has published 27 symposium issues based on Health Law Conferences and
Roundtables as well as 13 articles from the endowed Stuart Rome lecture. These have
included manuscripts by Prof. Lawrence Gostin from Georgetown University, Prof.
William Sage from University of Texas, Prof. Robert Burt and more recently, Prof. Abbe
Gluck, from Yale Law School, Nancy-Ann DeParle, the former director of the Centers
for Medicare and Medicaid Services, and Daniel Levinson, Inspector General for the
U.S. Dept. of Health and Human Services, among others. Hoffmann concluded by
praising the Journal for providing students with an invaluable opportunity to learn from
leading scholars about many different areas of health law and policy.

Former Editors-in-Chief Adrian Wilairat ’06, now Writer-Editor for the U.S. Department of Justice at the Office for
Victims of Crimes, and Deepti Kulkarni ’08, an associate attorney at Sidley Austin, echoed Professor Hoffmann’s
sentiments, sharing their reflections on their experience working on the Journal and expressing gratitude for the skills
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developed during their respective tenures. Current faculty advisor to the Journal, Professor Frank Pasquale, then shared his
thoughts on the bright future ahead for the Journal. The speakers were followed by the presentation of awards to authors
and student contributors who published the most cited publications in the Journal. The Editors-In-Chief who marshalled
these important manuscripts to publication were also recognized. A complete list of awardees is included below.

Award of Scholarly Excellence

•
•
•
•
•
•
•
•
•
•

(Awarded to individuals who published the most cited publications)
Paul Steven Miller, Is there a Pink Slip in My Genes? Genetic Discrimination in the Workplace
Sara Rosenbaum, Medicaid at Forty: Revisiting Structure and Meaning in a Post-Deficit Reduction Act Era
Robert A. Mikos, Preemption Under the Controlled Substances Act
Theresa Glennon, The Stuart Rome Lecture: Knocking Against the Rocks: Evaluating Institutional Practice and the
African-American Boy
Paul Arshagouni, “But I’m an Adult Now … Sort of” Adolescent Consent in Health Care Decision-Making and the
Adolescent Brain
Elizabeth Tobin Tyler, Allies Not Adversaries: Teaching Collaboration to the Next Generation of Doctors and Lawyers
to Address Social Inequality
Jennifer L. Pomeranz, Compelled Speech Under the Commercial Speech Doctrine: The Case of Menu Label Laws
Deborah Kaplan, The Definition of Disability: Perspective of the Disability Community
Adrian Wilairat, Faster, Higher, Stronger? Federal Efforts to Criminalize Anabolic Steroids and Steroid Precursors
Ellen A. Callegary, The IDEA’s Promise Unfulfilled: A Second Look at Special Education & Related Services for
Children with Mental Health Needs After Garret F

Award of Scholarly Excellence - Student Publications

•
•
•
•
•
•
•
•
•
•

(Awarded to individuals who published the most cited student publications)
Adrian Wilairat, Faster, Higher, Stronger? Federal Efforts to Criminalize Anabolic Steroids and Steroid Precursors
Erin Myers, The Manipulation of Public Opinion by the Tobacco Industry: Past, Present, and Future
Carrie A. Roll, The Human Papillomavirus Vaccine: Should It Be Mandatory or Voluntary?
Jake Schaller, Not for Bathing: Bath Salts and the New Menace of Synthetic Drugs
Lucy W. Shum, Educationally Related Mental Health Services for Children with Serious Emotional Disturbance:
Addressing Barriers to Access Through the IDEA
Amanda S. Pitcher, Contrary to First Impression, Genes are Patentable: Should There be Limitations?
Samantha Schad, Adolescent Decision Making: Reduced Culpability in the Criminal Justice System and Recognition
of Capability in Other Legal Contexts
Sara Klemm, Keeping Prevention in the Crosshairs: A Better HIV Exposure Law for Maryland
Michael J. McKeefery, A Call to Move Forward: Pushing Past the Unworkable Standard That Governs Undocumented
Immigrants’ Access to Health Care Under Medicaid
Anne Erikson Haffner, The Increasing Necessity of the Tort System in Effective Drug Regulation in a Changing
Regulatory Landscape

Citation for Outstanding Service

(Awarded to Editors-in Chief who published the ten most cited publications)
M. Jason Brooke
Rebecca Wizeman Hall
Deepti A. Kulkarni
Melissa M. McDonnell
Marc A. Nardone
Scott D. Nelson

Michael J. Pappas
Melanie Santiago
Amy F. Siegel
Sally Terese Vecchio
Nisha Wagle
Adrian Wilairat
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Dr. Aaron Kesselheim Delivers 2018 Rome
Lecture on Drug Pricing
On March 8, 2018, the Law &
Health Care Program and the
Center on Drugs and Public
Policy at the University of
Maryland School of Pharmacy
co-sponsored the 2018 Stuart
Rome Lecture and follow
on panel, “Drug Pricing and
Prospects.” The Stuart Rome
Lecture was established in 1984
to honor the memory of Stuart
Rome, a prominent health law
attorney, community activist,
art patron, and humanitarian in
the Baltimore Area. This year’s
lecture was delivered by Aaron
Kesselheim, MD, JD, MPH.
Dr. Kesselheim is the Director
of the Program on Regulation,
Therapeutics and Law
(PORTAL) in the Division
of Pharmacoepidemiology &
Pharmacoeconomics, Department
of Medicine, Brigham and
Women’s Hospital as well as an
Associate Professor of Medicine
at Harvard Medical School.
His research focuses on the
effects of intellectual property
laws and regulatory policies on
pharmaceutical drug development
and the cost and availability of
prescription drugs.
Drug prices have increased
dramatically in recent years. In
2015, prescription drug spending
in the United States increased
by 12% and again by 6% in
2016 to a total of $450 billion,
accounting for one-fifth of all
health care spending. The bulk of
this money is directed to brand
name drugs, which account
for 72% of all drug spending
although they comprise only
10% of prescriptions. Generic
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Dr. Aaron Kesselheim delivers Rome Lecture.

drug prices have also increased
dramatically. Dr. Kesselheim provided
a detailed overview of the current
state of prescription drug pricing in
the U.S. and the clinical consequences
of increases, including lower patient
adherence when more expensive brand
name drugs are prescribed instead of a
more affordable generic.
He then dispelled several myths
about price increases such as industry
arguments that such increases are
necessary to support innovation.
Kesselheim noted that there is no
association between research and
development costs and drug prices.
Most research and development
for new drug products is conducted
in academic institutions receiving
public funding from entities such as
the National Institutes of Health. In
addition, according to an analysis
conducted by Dr. Kesselheim and
Dr. Ameet Sarpatwari ‘13, drug
manufacturers spend only 10-20% of
revenue on research and development
in contrast to 20-30% on marketing
and administration costs and the 2030% paid to shareholders.

Kesselheim also disputed the assertion
that onerous regulatory hurdles at
the FDA are driving price increases,
noting widespread use of expedited
approval pathways by the majority
of new drugs as well as faster FDA
approval times than counterparts in
Europe and Canada.
Kesselheim asserted that drug prices
are rising because pharmaceutical
companies are allowed to charge
whatever the market will bear while
employing strategies that undercut
competition and hinder the ability of
payers to provide counterweights that
might reduce high prices. He then
discussed various policy solutions
that might be employed based on
where the drug product is in the drug
development "life cycle."
Market Exclusivity Period
In the initial post approval period, new
brand-name drugs are guaranteed six
to seven years of market exclusivity
with longer periods granted for new
antibiotics and biologics. Drugs also
enjoy patent protections. In addition
to the advantages of exclusivity,

manufacturers further benefit from
limits on public payers. Medicare, for
example, is unable to negotiate drug
prices. Private payers are also limited in
their ability to negotiate lower prices,
primarily due to the lack of comparative
effectiveness data available at the
time of approval as well as state law
coverage requirements.
Kesselheim offered several
countermeasures to the problem such as
authorization for public payers to use
formularies and negotiate drug prices
(currently prevented under the Medicare
Part D statute) or use international
reference pricing so that U.S. drug
prices remain in line with what other
countries are paying manufacturers.
There are additional policy
opportunities at the provider level to
address drug pricing as evidenced by
California’s recent effort to prohibit
manufacturer coupons and discounts
for brand name drugs when a generic
is available. While the consumer is
shielded from price increases via
copay coupons, payers must pay for
the increases associated with these
drugs. Other efforts at the provider
level include integration of value-based
prescribing into professional education
or through electronic medical record
point-of-care reminders.
Transition From Brand Name to
Generic
Kesselheim noted that the availability
of generic versions of brand-name
products is the most important factor
in drug pricing. As brand name drugs
reach the end of their market exclusivity
period, however, manufacturers have
become adept at taking steps to extend
exclusivity through, for example,
payments to generic producers in
exchange for dropping lawsuits to
gain market access or the development
of “a thicket of secondary patents.”
Other strategies include manufacturer
refusal to provide samples to generic
manufacturers, which are required to
conduct bioequivalence studies.

Drs. Frank Palumbo and Bill Padula (l.)

At this stage in the life cycle,
Kesselheim sees several opportunities
for reducing drug prices including a
review of settlements between generic
and brand name manufacturers.
Generic Competition Phase
Once the exclusivity period ends,
generic manufacturers enter the market
and, in theory, competition between
them drives down prices. In practice,
Kesselheim noted, there are fewer
competitors in the U.S. market than in
other countries. He proposed several
solutions to address the lack of market
competition including importation of
generics from well-regulated markets
in other countries and changes to
the regulatory framework that can
stimulate increased competition
such as expedited review of generic
applications when there are three or
fewer drugs in the market.
There is a pressing need to address the
cost of prescription drugs, Kesselheim
concluded, as increasing prices
will continue to result in negative
consequences for patients and the
entire health system. Dr. Kesselheim’s
lecture was followed by a panel
of experts on pharmaceutical drug
pricing.
Frank Palumbo, JD, PhD, Executive
Director of the Center on Drugs
and Public Policy at the University
of Maryland School of Pharmacy,
provided an overview of pharmacy

benefit managers and their role in drug
costs.
Joshua Auerbach, Esq., Special
Assistant & Senior Litigation Counsel,
Maryland Office of the Attorney
General, discussed the Maryland antiprice gouging statute and subsequent
litigation brought by generic
manufacturers. The Maryland statute
was challenged shortly after it passed
in 2017 by the professional association
of generic drug manufacturers
(Association for Accessible Medicines
v. Frosh). In April 2018, a threejudge panel of the U.S. Court of
Appeals for the Fourth Circuit held
that the Maryland statute violates the
dormant commerce clause by directly
regulating the price of transactions
outside of the state. Maryland Attorney
General Brian Frosh has requested that
the full court rehear the case.
William V. Padula, PhD, MS, MSc,
Assistant Professor, Department of
Health Policy & Management, Johns
Hopkins Bloomberg School of Public
Health, provided an overview of
approaches other states have taken to
stem increases in prescription drug
costs. Finally, Ameet Sarpatwari,
JD (‘13), PhD, Assistant Director of
PORTAL, discussed the market for
biologics and biosimilars, noting that
FDA has approved few biosimilars,
making competition in the biologics
space unlikely.
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Clinic Spotlight: Civil Rights of
Persons with Disabilities Clinic
Students with interest in health
law have several options available
to them in order to obtain
professional experience during
their studies including three
health law clinics and more than
two dozen externship placement
opportunities. The Civil Rights of
Persons with Disabilities Clinic,
one of the oldest disability rights
clinics in the country, has been
providing legal services to clients
with disabilities since 1975.
Clinic History
Professor Emeritus Susan Leviton
founded the clinic, then called
the Developmental Disabilities
Clinic, the same year that
Congress passed the Education
for All Handicapped Children Act
(later renamed the Individuals
with Disabilities Education Act,
or IDEA). The law required all
public schools to provide children
with disabilities equal access to
education and mandated provision
of special services to meet the
specific needs of children with
disabilities. That statute came
two years after the passage of the
Rehabilitation Act of 1973, the
first federal civil rights law for
individuals with disabilities. The
EAHCA gave parents a role in the
educational process and facilitated
parental involvement with schools
to identify and secure what their
children needed to be successful.
Professor Leviton recalls, “These
laws, the Rehabilitation Act
and the EAHCA, marked the
beginning of a new era. Prior to
their passage, parents of children
with disabilities were encouraged
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to institutionalize them. This was a
completely new area of the law and a
tremendous learning opportunity for
our students.”
In 1983, Professor Stanley Herr, a
longtime disability advocate, joined
the law school faculty and assumed
leadership of the clinic. Professor
Herr’s contributions to disability
rights are well documented. In
the early 1970s, he served as lead
counsel in Mills vs. Board of
Education where the legal team
successfully argued for access to
public education for all children
including those with disabilities.
That landmark decision later
provided the foundation for the
EACHA. By all accounts, Herr
was an indefatigable disability
rights advocate, receiving honors
from many organizations in his
career including The ARC and the
American Bar Association.
Through their work with the
Maryland Disability Law Center
(now Disability Rights Maryland),
Prof. Herr befriended Marc
Charmatz, an attorney with the
National Association of the
Deaf (NAD), a grassroots civil
rights advocacy organization that
represents deaf and hard of hearing
individuals. In 1999, when Herr took
a sabbatical from the law school, he
asked Charmatz to lead the clinic in
his absence. Sadly, Prof. Herr was
unable to return to his role, dying
from cancer in 2001.
Prof. Charmatz carried on Herr’s
legacy and assumed leadership of
the clinic for the next 18 years.
During that time, he continued to
serve as litigation counsel at NAD

Professor Emeritus Susan Leviton

and began to combine his work there
with his work at the clinic. Charmatz
recalls, “While I have tremendous
respect for those engaged in work at the
policy level, I am client-driven - I want
to represent individuals, particularly
those having difficulty finding counsel.
I knew we had plenty of clients in need
of representation at NAD. I realized
that working in collaboration with
NAD would be a great educational
tool to teach students about real-world
legal representation in the context of
disability rights.”
In recognition of his contributions,
Charmatz’s work as an advocate
for individuals with disabilities was
recently featured in an article in the
ABA Journal magazine discussing

Professors Stanley Herr and Diane Hoffmann,
circa 1995

the origins and achievements of the
disability rights movement.
In 2014, Charmatz recruited Caroline
Jackson, Staff Attorney with NAD,
to serve as co-instructor. He stepped
down from his role directing the clinic
after the Spring 2017 semester; Anna
Bitencourt joined as clinic co-director
in fall 2017. Prof. Bitencourt currently
serves as a staff attorney and Director
of Intake at NAD.

Marc Charmatz

Prof. Jackson joined the NAD as a
Skadden Fellow after law school.
Long interested in disability rights,
Jackson worked as a sign language
interpreter in New York City before
returning to school to pursue her
law degree. Prof. Bitencourt, who
is deaf, worked in private practice
for several years after law school
and occasionally received referrals
or requests for assistance in cases
involving deaf clients from the NAD.
She began working at NAD parttime and was then invited to join the
organization on a full-time basis to
direct client intake and litigate cases.

foundation in disability law including
the Americans with Disabilities Act,
the Rehabilitation Act as well as
related laws in the areas of education,
employment and public benefits.
Clinic students handle cases at all
stages of legal proceedings, including
initial client interviews, drafting
pleadings, counseling, discovery,
motions practice, trial and appeal.
Through their participation in the
clinic, they develop an understanding
of the public policy issues that
influence the ability of individuals
with disabilities to participate
in society as well as the various
stakeholders involved in protecting
and promoting disability rights.
Many of the cases students handle
address issues of communication
access for deaf and hard of hearing
individuals. Deaf and hard of hearing
individuals and their family members
face obstacles in a variety of settings
from schools to health care institutions
to jails where deaf individuals lack
access to the tools necessary to
allow for effective communication
and adequate engagement. Students
participate fully in the intake process,
receiving initial calls from potential
clients, learning how to communicate
with clients and obtain facts about
their case.Students work closely
with Ms. Bitencourt to review the
facts of each case and determine if

Training Students to Advocate for
Civil Rights
Jackson and Bitencourt work with
student attorneys to represent clients
with disabilities in a variety of
settings and collaborate with other
organizations involved in broad impact
litigation.
The classroom component of the
clinic provides students with a

Clinic Co-Directors Caroline Jackson
and Anna Bitencourt

The clinic handles a wide variety
of cases – education, employment,
and access to health care. Last year,
for example, students represented
an individual who was denied
admission to a radiology technician
training program because she was
deaf. That case went to jury trial
and was ultimately resolved in the
client’s favor. Students also engage
in advocacy outside the courtroom,
drafting demand letters on behalf of
clients to ensure that accommodations
such as captioning and interpreters
will be provided in various contexts.
In addition to the nuts and bolts of
litigation and advocacy, students
learn about deaf culture and work
closely with deaf professionals.
They also learn about the protection
and advocacy system established by
federal law to protect disability rights.
Many of the clinic’s student attorneys
have continued to advocate for the
rights of individuals with disabilities.
Munib Lohrasbi ‘17, an alumnus of
the law school and former student
attorney with the clinic, was awarded
an Open Society Institute-Baltimore
Community fellowship to improve
conditions for people with disabilities
in prison in Maryland. He is working
with Maryland’s federally mandated
Protection & Advocacy agency,
Disability Rights Maryland, to
inspect state prison facilities and
evaluate current assessment and
accommodation procedures for
individuals with disabilities.
Other graduates have gone on to
hold positions at the Department of
Justice and disability rights advocacy
organizations in other states, a
testament to the clinic’s lasting impact
on students.

it is suitable for litigation. Caroline
Jackson supervises the litigation
component.
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Microbiota Transplant
Project Update
Professor Diane Hoffmann and coinvestigators from the University of
Maryland Schools of Law, Pharmacy
and Medicine hosted the final meeting
of the Microbiota Transplantation
Working Group on February 23,
2018. The meeting was the fourth
in a series of meetings supported by
Professor Hoffmann’s NIH-funded
project, Microbiota-Transplantation:
Recommendations for a Regulatory
Framework.

seeding, where newborns delivered
via caesarean section are swabbed
with the mother’s vaginal fluids
to mimic the transfer that happens
during vaginal births. Several industry
representatives gave presentations on
new microbiome-based diagnostics.
After the presentations, members
broke into small groups to discuss
the ethical and legal implications of
microbiome-based diagnostics and
therapeutics.

The working group comprises experts
and stakeholders including physicians,
researchers, bioethicists, lawyers, as
well as representatives from private
industry engaged in microbiota
transplantation. In addition to updates
on fecal microbiota transplantation
(FMT) and stool-based drugs, the final
meeting also included presentations on
newer areas of research such as vaginal
microbiota transplants and vaginal

The meeting was the first since
the publication of the article,
“Improving regulation of microbiota
transplants,” in the journal Science in
December 2017. That article, based
in part on the prior working group
meetings, proposes a framework for
the regulation of fecal microbiota
transplantation (FMT). Hoffmann and
her co-authors propose a three-track
framework that aims to balance patient

access with safety and effectiveness
concerns. The framework requires
increasing regulatory oversight based
on source of stool (e.g. person known
to patient vs. stool bank) and level
of processing (stool vs. stool-based
products).
The article is available to download
via Prof. Hoffmann’s faculty profile on
the law school website.
Hoffmann also presented on the topic
at an educational session held by
the American Gastroenterological
Association at the Crohns & Colitis
Foundation’s Annual Meeting in Las
Vegas in January.

Maryland Carey Law Faculty Address the Opioid Epidemic
Continued from Page 5:
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Maryland Carey Law Teams Prevail in
7th Annual Health Law Regulatory and
Compliance Competition

Maryland Carey Law students Eli Sherlock, Ashley Creech, and Kellie Taylor took first place;
classmates Jessica Ramdat and Jennifer Ponce-Mejia placed third.

The Seventh Annual Health Law
Regulatory and Compliance
Competition was held on Saturday,
February 23, 2018 at Maryland Carey
Law. More than 30 students from nine
law schools competed in the event this
year.
Maryland Carey Law took first place
in the competition. Team members
(pictured above) Ashley Creech,
Kellie Taylor, and Elias Sherlock
were coached by Sean Gugerty ‘15
and Samantha Collado ‘16. The
other winning teams were American
University Washington School of
Law (second place) and the second
University of Maryland team (third
place).
Students were given 90 minutes to
analyze a hypothetical fact pattern
involving various interactions between
health care stakeholders and entities
engaged in activities that necessitate
regulatory and compliance oversight.
Participants then present their findings

and recommendations to a panel of
practicing health lawyers. Nearly
30 attorneys from a broad range
of organizations served as judges,
including CMS, FDA, law firms
and private industry. This year’s
competition focused on healthcare
fraud and abuse, rural hospitals,
payers, credentialing and challenges
associated with telehealth services
implementation, payment and
reimbursement.
Professor Diane Hoffmann
commended the students for their
participation, noting, “The competition
provides students with a glimpse
of real-life health law practice by
tackling complex matters that require
thoughtful and thorough analysis and
a time-sensitive response. All of the
participants should be proud of their
performance today.”

Association, provided the keynote
address and congratulated the
participants on both their participation
in the competition and decision to
pursue careers in health law. Mr.
Cade then announced the winners and
presented the awards. Students on the
winning teams also received prizes
generously donated by the American
Health Lawyers Association and the
Food and Drug Law Institute.
The competition received generous
support from the following sponsors:
Premier Sponsor: Baker Donelson
Platinum Sponsors: American Health
Lawyers Association, Berkeley
Research Group
Gold Sponsors: Arnold & Porter, Food
and Drug Law Institute

At the luncheon following the
competition, David Cade ‘85, CEO
of the American Health Lawyers
Law & Health Care Program
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7th Annual Health Law Regulatory and
Compliance Competition

From top left: The American University team; American Health Lawyers Association CEO David Cade ‘85
delivers the keynote adddress; Prof. Diane Hoffmann welcomes participants and judges.

Law & Health Care Program Collaborates
with Johns Hopkins Berman Institute of
Bioethics on Faculty Retreat
On April 11, 2018, faculty from the Law & Health Care Program
participated in a collaborative retreat with faculty from the Johns Hopkins
Berman Institute of Bioethics. Although L&HCP faculty members Karen
Rothenberg and Leslie Henry have held affiliate faculty appointments at
the Berman Institute for many years, the retreat marked the first time that
faculties from both programs had the opportunity to meet and discuss
current research interests. The day’s schedule included brief presentations
from faculty on their research in three areas: new and emerging
technologies, infectious diseases, and opioids and pain. The presentations focused not only on current progress but
encouraged discussion on the relationship of the different topic areas to issues of justice and the identification of research
questions that would benefit from interdisciplinary collaboration.
“The retreat is the first of hopefully many such events bringing together the health law and Berman faculties. There
was a lot of enthusiasm from the retreat attendees about possible collaborations. I am looking forward to the continued
development of these ideas with our Berman colleagues,” remarked Diane Hoffmann, Director of the Law & Health Care
Program.
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Law & Health Care Program News
Leslie Henry

Karen Rothenberg

Leslie Henry was a co-author on the research white paper
“Biorepositories: Addendum to Registries for Evaluating
Patient Outcomes: A User’s Guide, Third Edition” prepared
for the Agency on Healthcare Research and Quality.

Prof. Rothenberg was quoted in “Is DNA testing telling us
more than we want to know? The untold story of Ancestry.
com,” on Deseret News on May 30, 2018.

Professor Henry was also a co-author on an article in the
journal Obstetrics & Gynecology, “Ethical Considerations
Concerning Amnioinfusions for Treating Fetal Bilateral
Renal Agenesis,”131(1):130-134, 2018.
Diane Hoffmann
Diane Hoffmann and campus colleagues published
“Improving Regulation of Microbiota Transplants,” in
Science in December 2017.

Prof. Rothenberg will serve as an Advisory Panel Member
for a National Palliative Care Research Center Pilot and
Exploratory Grant titled: “What it means for our family
– Video Decision Supports for Parents Considering
Chronic Pediatric Mechanical Ventilation,” a multicenter
collaboration with the Johns Hopkins School of Medicine,
the University of Mississippi Medical Center and Seattle
Children’s Hospital.
Amanda Pustilnik

Diane Hoffmann was quoted and her article, “The Girl who
Cried Pain,” was cited in the Atlantic on January 23, 2018 in
the segment “Larry Nassar and the Impulse to Doubt Female
Pain.”

Amanda Pustilnik published “The Law’s Responses to
the Opioid Epidemic: Legal Solutions to a Unique Public
Health, Criminal Law, and Market-Related Crisis” in
Confronting Our Nation’s Opioid Crisis: A Report of the
Aspen Health Strategy Group.

Hoffmann was a guest on NPR’s All Sides with Ann Fisher
appearing with Abby Norman, author of Ask Me about My
Uterus: A Quest to Make Doctors Believe in Women’s Pain
(April 26, 2018).

Amanda Pustilnik published “Legal Evidence of
Subjective States: A Brain-Based Model of Chronic Pain
Increases Accuracy and Fairness in Law,” 25 Harv. Rev. of
Psychiatry 279 (2017).

The Washington Post published a Letter to the Editor by
Hoffmann and Kate Nicholson on efforts by Human Rights
Watch to investigate the impact of opioid limits on chronic
pain patients (May 6, 2018).

Amanda Pustilnik published “Brain imaging tests for
chronic pain: medical, legal and ethical issues and
recommendations,” with Karen D. Davis, Herta Flor,
Henry T. Greely, Gian Domenico Iannetti, Sean Mackey,
Markus Ploner, Irene Tracey, Rolf-Detlef Treede, & Tor D.
Wager, 13 Nature Rev. Neurology 624 (2017).

Kathleen Hoke
Kathleen Hoke was appointed to the Food and Drug Law
Institute Tobacco Products Committee for 2018.
Prof. Hoke was quoted in “From Opioids to Guns: Cities,
Counties Step Up Civil Suits,” an article published on
Bloomberg News in March 2018.
Frank Pasquale

L&HCP Students
Health law student Mena Gaballah ‘18 co-authored a
March 2018 op-ed in the Baltimore Sun with colleagues
from the R. Adams Cowley Shock Trauma Center at the
University of Maryland Medical Center, warning of abuse
of the popular over-the-counter drug, Imodium.

Public Health Law Clinic student Adrienne Thomas (3L)
testified before the Maryland General Assembly in support
Prof. Frank Pasquale was featured in the December 2017
of House Bill 315 (Maryland Cares for Kids Act), a bill
issue of the ABA Journal in the article “Defense lawyers
want to peek behind the curtain of probabilistic genotyping.” that would require the State to cover costs associated with
reduced breakfast and lunch to expand access for lowincome students.
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Law & Health Care Program
500 West Baltimore Street
Baltimore, MD 21201
www.law.umaryland.edu/healthlaw
Comments and letters should be
forwarded to the above address.

The Week in Health Law Podcast
Tune in to The Week in Health Law, a weekly podcast hosted by our own
Professor Frank Pasquale and Professor Nicolas Terry, Executive Director
of the Hall Center for Law and Health at Indiana
University McKinney School of Law. The podcast
engages various guests in conversations about a
wide range of issues in health law and policy.
To access this podcast, search for The Week in
Health Law on your favorite podcast app. Show
notes appear at twihl.com.

